Product Reports Resources Pricing Login Book a demo

Arrowhead Pharmaceuticals

Biotech & Life Sciences · Pasadena, United States · Founded 2003 · Public via SPAC 2004

Gene silencing platform targeting liver, lung, CNS, and metabolic diseases

Valuation $11B
Revenue $442M

Investors

4 investors on Arrowhead Pharmaceuticals's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 4 investors entered at this stage

Global footprint

Where Arrowhead Pharmaceuticals has talent and traffic

Workforce by country
🇺🇸 United States · Pasadena HQ
Book a demo for the full country breakdown
Web traffic by country
43K monthly visits
across markets
🇺🇸 United States74.2%
🇬🇧 United Kingdom4%
🇳🇬 Nigeria3.5%
🇮🇳 India3.3%
🏳️ Korea3%
Top 5 markets shown

Talent graph

The shape of Arrowhead Pharmaceuticals's talent

Dealroom maps Arrowhead Pharmaceuticals's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

28 standout operatorsDealroom-flagged across the org
1 AI specialistpinpointed by name
746 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Arrowhead Pharmaceuticals's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$200M patent portfolio · 130 active families

Estimated portfolio value
$200M
1.8% of market cap · 3.2× larger than top peer Palvella Therapeutics ($62M)
130 active patent families
Where Arrowhead Pharmaceuticals innovates Cell biologyDiseaseGene expressionHepatocyteIn vivo

Where Arrowhead Pharmaceuticals concentrates vs peers

Each axis is a top-10 topic across Arrowhead Pharmaceuticals and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Arrowhead Pharmaceuticals's 3 investments and acquisitions.

Every disclosed deal where Arrowhead Pharmaceuticals appeared as a backer or acquirer, 2006–2022. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

3 deals across Arrowhead Pharmaceuticals's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        Arrowhead Pharmaceuticals's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        3 of 3 deals

        Market sentiment

        What the market is saying about Arrowhead Pharmaceuticals

        An AI-synthesized read of the highest-engagement posts about Arrowhead Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Arrowhead Pharmaceuticals on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.